Despite its potential, single-cell analysis poses significant throughput challenges in generating the vast datasets necessary for comprehensive biological study.

In this Q&A, Sonja Strunz, head of the regulatory affairs department at Limbus Medical Technologies in Germany, explains the classification of devices under IVDR and what it means for manufacturers, users, and patients.

With advance planning and a diagnostics partner with demonstrated regulatory expertise, it is possible to navigate EU IVDR requirements with confidence and keep clinical trial timelines on track.

Explainable artificial intelligence, or XAI, is enabling Baylor Genetics to hasten and scale up clinical whole-genome sequencing while testing becomes more accessible and evidence for its utility grows.

Artificial intelligence models that can explicitly demonstrate their logic and expose potential biases, known as explainable AI, or XAI, are necessary for medical institutions to make healthcare decisions with increased confidence, according to Illumina. 

The panel concluded that the test has the potential to aid in the early diagnosis of sepsis and to guide and monitor response to therapy.

Epigenetics is the key to unlocking the full potential of cancer therapy, including immunotherapies, by revealing deep insights into how the body reacts and responds to medication.

Officially launched at the International Conference on Genomics in 2019, the Million Microbiome of Humans Project aims to sequence and analyze microbial DNA from one million human samples in three to five years, focusing on feces and saliva, to construct a microbiomic map of the human body — primarily using MGI’s DNBSEQ sequencing technology.